No Data
No Data
Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating
Positive Outlook for Viking Therapeutics Amid Promising Trial Developments
Viking Therapeutics' Oral-2735 Could Differentiate Asset, Says JPMorgan
This Insider Has Just Sold Shares In Viking Therapeutics
Viking Therapeutics Analyst Ratings
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102